Q2 Report: Merck on track
Advertisement
“Merck’s solid business performance continued into the second quarter of 2013, with total revenues increasing organically by 3% even in a more difficult market environment. Our ‘Fit for 2018’ program is producing excellent results with the second-quarter EBITDA pre one-time items up 11%,” said Karl-Ludwig Kley, Chairman of the Executive Board of Merck. “Therefore, we can confirm our full-year guidance of € 3.1 to 3.2 billion EBITDA pre despite currency headwinds.”
Merck reported an organic increase in total revenues of 2.8% in the second quarter of 2013. Negative currency effects of -3.4% caused total revenues of the Merck Group to fall slightly by -0.4% to € 2,841 million (Q2 2012: € 2,852 million). In the first half of 2013, total revenues of the Merck Group increased by 1.9% to € 5,602 million (January-June 2012: € 5,497 million). Sales (total revenues less royalty, license and commission income) grew organically by 3.3% in the second quarter of 2013 but the increase was offset by negative currency effects of -3.5%. Overall, second-quarter Group sales totaled € 2,744 million (Q2 2012: € 2,743 million). In the first half of 2013, sales rose 1.8% to € 5,404 billion (January – June 2012: € 5,307 million).
Other news from the department business & finance
